bluebird bio, Inc. (BLUE)
NASDAQ
Market Cap
$80.16M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
573 of 951
Rank in Industry
311 of 544
Largest Insider Buys in Sector
BLUE Stock Price History Chart
BLUE Stock Performance
About bluebird bio, Inc.
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company's clinical study program includes HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has strategic collaboration and license agreements with Orchard Therapeutics Limited, Forty Seven, Inc., and Magenta Therapeutics, Inc. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Cambridge, Massachusetts.
Insider Activity of bluebird bio, Inc.
Over the last 12 months, insiders at bluebird bio, Inc. have bought $0 and sold $61,070 worth of bluebird bio, Inc. stock.
On average, over the past 5 years, insiders at bluebird bio, Inc. have bought $0 and sold $503,710 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 19,364 shares for transaction amount of $1M was made by Leschly Nick (President and CEO) on 2015‑12‑08.
List of Insider Buy and Sell Transactions, bluebird bio, Inc.
| 2025-01-06 | Sale | President and CEO | 140 0.0013% | $9.24 | $1,294 | -15.42% | ||
| 2025-01-06 | Sale | Chief Medical Officer | 19 0.0002% | $9.24 | $176 | -15.42% | ||
| 2024-12-10 | Sale | President and CEO | 971 0.0005% | $0.42 | $405 | +0.66% | ||
| 2024-12-10 | Sale | Chief Medical Officer | 2,824 0.0014% | $0.42 | $1,178 | +0.66% | ||
| 2024-09-30 | Sale | President and CEO | 34,780 0.0189% | $0.53 | $18,270 | -14.97% | ||
| 2024-09-30 | Sale | See Remarks | 1,006 0.0005% | $0.53 | $529 | -14.97% | ||
| 2024-06-03 | Sale | See Remarks | 3,834 0.002% | $0.97 | $3,726 | -46.03% | ||
| 2024-03-04 | Sale | President and CEO | 6,095 0.0031% | $1.53 | $9,311 | -41.08% | ||
| 2024-03-04 | Sale | See Remarks | 4,573 0.0023% | $1.53 | $6,986 | -41.08% | ||
| 2024-03-01 | Sale | Chief Medical Officer | 6,770 0.0034% | $1.53 | $10,342 | -42.33% | ||
| 2024-02-05 | Sale | President and CEO | 1,879 0.0008% | $0.90 | $1,696 | +1.52% | ||
| 2024-02-05 | Sale | See Remarks | 2,714 0.0012% | $0.90 | $2,449 | +1.52% | ||
| 2024-02-05 | Sale | Chief Business & Legal Officer | 5,217 0.0023% | $0.90 | $4,708 | +1.52% | ||
| 2024-01-05 | Sale | President and CEO | 3,162 0.0016% | $1.43 | $4,520 | -33.27% | ||
| 2024-01-05 | Sale | Chief Medical Officer | 597 0.0003% | $1.42 | $845 | -33.27% | ||
| 2023-12-06 | Sale | Chief Financial Officer | 4,526 0.0039% | $4.52 | $20,437 | -79.64% | ||
| 2023-11-03 | Sale | President and CEO | 807 0.0007% | $3.17 | $2,555 | -70.40% | ||
| 2023-11-02 | Sale | Chief Medical Officer | 2,343 0.0021% | $2.98 | $6,975 | -66.23% | ||
| 2023-09-05 | Sale | See Remarks | 922 0.0009% | $3.79 | $3,493 | -66.98% | ||
| 2023-08-10 | Sale | President and CEO | 16,929 0.0168% | $3.54 | $59,956 | -59.47% |
Insider Historical Profitability
54.67%
| Klima Thomas J | See Remarks | 170000 1.7486% | $8.25 | 0 | 7 | |
| Vittiglio Joseph | Chief Business & Legal Officer | 44783 0.4606% | $8.25 | 0 | 1 | |
| Obenshain Andrew | President and CEO | 18571 0.191% | $8.25 | 0 | 20 | |
| Colvin Richard A | Chief Medical Officer | 8257 0.0849% | $8.25 | 0 | 7 | |
| TEPPER ROBERT I | 1215054 12.4977% | $8.25 | 0 | 9 | ||
| THIRD ROCK VENTURES LP | 10 percent owner | 1215054 12.4977% | $8.25 | 0 | 9 | |
| GILLIS STEVEN | director | 1041111 10.7086% | $8.25 | 0 | 7 | |
| Leschly Nick | director | 280149 2.8815% | $8.25 | 1 | 49 | <0.0001% |
| Cole Jason | Chief Strategy & Financial Off | 189546 1.9496% | $8.25 | 0 | 39 | |
| Whitten Jessica | Chief Accounting Officer | 49413 0.5082% | $8.25 | 0 | 3 | |
| Davidson David | Chief Medical Officer | 47787 0.4915% | $8.25 | 0 | 95 | |
| Gregory Philip D | Chief Scientific Officer | 46829 0.4817% | $8.25 | 0 | 56 | |
| Krawtschuk Christopher | Chief Financial Officer | 45474 0.4677% | $8.25 | 0 | 1 | |
| Eggimann Anne-Virginie | Chief Regulatory Officer | 42252 0.4346% | $8.25 | 0 | 1 | |
| Walsh Jeffrey T. | Chief Strategy Officer | 40921 0.4209% | $8.25 | 0 | 57 | |
| Baird William D III | Chief Financial Officer | 35529 0.3654% | $8.25 | 0 | 4 | |
| FINGER ALISON CECILY | Chief Commercial Officer | 25103 0.2582% | $8.25 | 0 | 14 | |
| Smith-Farrell Joanne | COO, Oncology | 20609 0.212% | $8.25 | 0 | 14 | |
| HIGH SUSANNA GATTI | Chief Operating Officer | 13750 0.1414% | $8.25 | 0 | 6 | |
| Leiderman Elisabeth | director | 11466 0.1179% | $8.25 | 0 | 1 | |
| WENTWORTH KORY JAMES | Principal Accounting Officer | 9512 0.0978% | $8.25 | 0 | 10 | |
| MARAGANORE JOHN | director | 5843 0.0601% | $8.25 | 2 | 4 | +99.03% |
| Sullivan Eric | Principal Accounting Officer | 5674 0.0584% | $8.25 | 0 | 25 | |
| Burnett Katy | Principal Accounting Officer | 4097 0.0421% | $8.25 | 0 | 2 | |
| Schenkein David P | director | 3176 0.0327% | $8.25 | 1 | 2 | +30.47% |
| LYNCH DANIEL | director | 2800 0.0288% | $8.25 | 0 | 21 | |
| Mandell James | director | 1000 0.0103% | $8.25 | 0 | 8 | |
| Bain Linda | VP, Fin. & Business Operations | 0 0% | $8.25 | 0 | 8 | |
| Finer Mitchell H. | Chief Scientific Officer | 0 0% | $8.25 | 0 | 16 | |
| Vachon Mark | director | 0 0% | $8.25 | 0 | 5 |
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
| BlackRock | $19.43M | 7.97 | 15.18M | +68.97% | +$7.93M | <0.0001 | |
| The Vanguard Group | $13.44M | 5.52 | 10.5M | +19.64% | +$2.21M | <0.0001 | |
| Granahan Investment Management | $9.87M | 4.05 | 7.71M | -4.53% | -$468,515.83 | 0.35 | |
| Ameriprise Financial | $8.18M | 3.36 | 6.39M | +131.96% | +$4.65M | <0.01 | |
| Millennium Management LLC | $7.99M | 3.28 | 6.24M | +82.78% | +$3.62M | 0.01 | |
| Palo Alto Investors Lp | $5.84M | 2.4 | 4.56M | +36.8% | +$1.57M | 0.66 | |
| Geode Capital Management | $5.53M | 2.27 | 4.32M | +82.23% | +$2.49M | <0.0001 | |
| State Street | $4.39M | 1.8 | 3.43M | -75.28% | -$13.36M | <0.0001 | |
| Two Sigma | $3.55M | 1.46 | 2.77M | -4.7% | -$175,065.61 | 0.01 | |
| Tang Capital Management, LLC | $3.2M | 1.31 | 2.5M | +47.06% | +$1.02M | 0.01 | |
| Fidelity Investments | $3.05M | 1.25 | 2.38M | +0.17% | +$5,176.32 | <0.0001 | |
| Renaissance Technologies | $2.8M | 1.15 | 2.19M | -17.09% | -$577,227.22 | <0.01 | |
| PFM Health Sciences | $2.61M | 1.07 | 2.04M | 0% | +$0 | 0.07 | |
| JPMorgan Chase | $2.47M | 1.02 | 1.93M | +10.09% | +$226,868.55 | <0.0001 | |
| Frazier Life Sciences Management L P | $2.19M | 0.9 | 1.71M | 0% | +$0 | 0.1 | |
| Dimensional Fund Advisors | $2.11M | 0.87 | 1.65M | -44.99% | -$1.73M | <0.01 | |
| Northern Trust | $2.08M | 0.85 | 1.62M | +62.08% | +$794,869.61 | <0.0001 | |
| Susquehanna International Group | $1.71M | 0.7 | 1.33M | -10.15% | -$192,727.07 | <0.01 | |
| Bank of America | $1.66M | 0.68 | 1.3M | -20.24% | -$420,652.94 | <0.0001 | |
| Morgan Stanley | $1.64M | 0.67 | 1.28M | +5.47% | +$84,925.49 | <0.0001 | |
| Alyeska Investment Group L P | $1.61M | 0.66 | 1.26M | -81.83% | -$7.24M | 0.01 | |
| Hudson Bay Capital Management LP | $1.51M | 0.62 | 1.18M | -45.95% | -$1.28M | 0.01 | |
| Two Sigma Advisers LP | $1.49M | 0.61 | 1.16M | +214.92% | +$1.01M | <0.01 | |
| Bleichroeder Lp | $1.33M | 0.55 | 1.04M | -58.51% | -$1.87M | 0.35 | |
| Masters Capital Management, LLC | $1.28M | 0.53 | 1M | 0% | +$0 | 0.24 | |
| Woodline Partners LP | $1.25M | 0.51 | 975,162 | +94.98% | +$608,022.86 | 0.01 | |
| Lion Point Capital LP | $1.09M | 0.45 | 848,256 | +59.67% | +$405,760.12 | 2.11 | |
| Jane Street Capital | $1.03M | 0.42 | 804,770 | +135.75% | +$593,147.81 | <0.01 | |
| Walleye Capital | $1M | 0.41 | 783,436 | New | +$1M | <0.01 | |
| Deutsche Bank | $934,822.00 | 0.38 | 730,330 | +4.94% | +$44,012.78 | <0.0001 | |
| Goldman Sachs | $871,437.00 | 0.36 | 680,810 | -46.67% | -$762,593.45 | <0.0001 | |
| D. E. Shaw & Co. | $872,023.00 | 0.36 | 681,268 | New | +$872,023.00 | <0.01 | |
| Wellington Management Company | $845,280.00 | 0.35 | 660,375 | +7.62% | +$59,819.52 | <0.0001 | |
| Jefferies Financial Group | $807,133.00 | 0.33 | 630,573 | 0% | +$0 | 0.01 | |
| BNY Mellon | $734,953.00 | 0.3 | 574,183 | +36.63% | +$197,041.59 | <0.0001 | |
| Group One Trading | $669,004.00 | 0.28 | 522,659 | -44.87% | -$544,557.19 | 0.01 | |
| Charles Schwab | $668,746.00 | 0.27 | 522,458 | +77.71% | +$292,427.41 | <0.0001 | |
| Nuveen | $524,617.00 | 0.22 | 409,857 | +32.52% | +$128,743.69 | <0.0001 | |
| Graham Capital Management, L.P. | $467,816.00 | 0.19 | 365,481 | -19.73% | -$115,004.24 | 0.02 | |
| Legal & General | $433,508.00 | 0.18 | 338,678 | +3,497.98% | +$421,459.35 | <0.0001 | |
| Mirae Asset Global Investments Co Ltd | $1.39M | 0.17 | 325,111 | +38.36% | +$384,638.46 | <0.01 | |
| AQR Capital | $411,360.00 | 0.17 | 321,375 | +71.14% | +$170,996.48 | <0.01 | |
| Birchview Capital Lp | $411,136.00 | 0.17 | 321,200 | 0% | +$0 | 0.02 | |
| CAPTRUST | $406,766.00 | 0.17 | 317,786 | +266.98% | +$295,923.14 | <0.0001 | |
| Simplex Trading Llc | $333,000.00 | 0.14 | 260,545 | +2.87% | +$9,303.22 | 0.01 | |
| Xtx Topco Ltd | $330,121.00 | 0.14 | 257,907 | +1,262.28% | +$305,888.04 | 0.01 | |
| RhumbLine Advisers | $298,506.00 | 0.12 | 233,217 | +40.44% | +$85,949.89 | <0.0001 | |
| Summit X Llc | $294,126.00 | 0.12 | 229,773 | +28.4% | +$65,054.54 | 0.08 | |
| LINSCO PRIVATE LEDGER CORP | $293,161.00 | 0.12 | 229,032 | +752.12% | +$258,757.15 | <0.0001 | |
| UBS | $280,480.00 | 0.12 | 219,125 | -68.03% | -$596,759.04 | <0.0001 |
Investing Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.